Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide

Hypertension

Volumn 29, Issue 3, 1997, Pages 757-762

  Siragy, Helmy M ^a   Jaffa, Ayad A ^b   Margolius, Harry S ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

bradykinin; cyclic GMP; interstitium; kidney; microdialysis; prostaglandin E2; sodium

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLIC GMP; ICATIBANT; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; BRADYKININ RECEPTOR; DRUG DERIVATIVE; ENZYME INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOG; DRUG EFFECT; ENZYME INHIBITION; KALLIKREIN KININ SYSTEM; KIDNEY CORTEX; KIDNEY FUNCTION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; DRUG INTERACTION; FEMALE; HEMODYNAMICS; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; DINOPROSTONE; DOGS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PROCESSES; INDOMETHACIN; KIDNEY; NITRIC OXIDE; OMEGA-N-METHYLARGININE; RECEPTORS, BRADYKININ; RENAL CIRCULATION;

EID: 0030614818     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.3.757     Document Type: Article

References (27)

1. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
2. Salvemini D, Seibert K, Masferrer JL, Misko TP, Curne MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest. 1994; 93:1940-1947.
3. Terragno NA, Lonigro AJ, Malik KU, McGiff JC. The relationship of the renal vasodilator action of bradykinin to the release of a prostaglandin E-like substance. Experientia. 1972;28:437-439.
4. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992;107:722-725.
5. Flamenbaum W, Gagnon J, Ramwell P. Bradykinin-induced renal hemodynamic alterations: renin and prostaglandin relationships. Am J Physiol. 1979;237:F433-F440.
6. Beierwalters W, Carretero OA, Scicli AG. Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol. 1988;255: F408-F414.
7. Carretero OA, Scicli AG. The renal kallikrein-kinin system. Am J Physiol. 1980;238:F247-F255.
8. Tomiyama H, Scicli AG, Scicli GM, Carretero OA. Renal effects of Fab fragments of kinin antibodies on deoxycorticosterone acetate-salt-treated rats. Hypertension. 1990;15:761-766.
9. 2, water, and sodium excretion. Hypertension. 1995;25:1008-1013.
10. Barabe J, Huberdeau D, Bernoussi A. Influence of sodium balance on urinary excretion of immunoreactive kinins in rats. Am J Physiol. 1988;254:F484-F491.
11. 2, and cyclic guanosine 3′,5′-monophosphate: effects of altered sodium intake. Hypertension. 1994;23(part 2):1068-1070.
12. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke St, Breipohl G, König W, Knolle J, Schölkens BA. HOE 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
13. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA. HOE 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
14. Siragy HM, Johns RA, Peach MJ, Carey RM. Nitric oxide alters renal function and guanosine 3′5′-cyclic monophosphate. Hypertension. 1992;19:775-779.
15. Siragy HM, Jaffa AA, Margolius HS. Stimulation of renal interstitial bradykinin by sodium depletion. Am J Hypertens. 1993;6:863-866.
16. Johnson MD, Malvin RL. Plasma renin activity during pentobarbital anesthesia and gradual hemorrhage in dogs. Am J Physiol. 1975; 229:1098-1101.
17. Dickstein GM, Woodson JF, Lamb NE, Rose CE Jr, Peach MJ, Carey RM. Escape from the sodium retaining action of intrarenal angiotensins II and III in the conscious dog. Endocrinology. 1985;117: 2160-2169.
18. Siragy HM. Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol. 1993;265:E648-E654.
19. Sealey JE, Laragh JH. How to do a plasma renin assay. Cardiovasc Med. 1977;2:1079-1092.
20. Shimamato K, Ando T, Nakoo T, Tanaka S, Sakum M, Miyahara M. A sensitive radioimmunoassay method for urinary kinins in man. J Lab Clin Med. 1978;91:721-728.
21. Harper JF, Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucl Res. 1975;1:207-218.
22. Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins. 1980;20:947-957.
23. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T. HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol. 1991;200:179-182.
24. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
25. Terragno NA, Malik KU, Nasjletti A, Terragno DA, McGiff JC. Renal prostaglandins. Adv Prostaglandin Thromboxane Res. 1976;2: 561-571.
26. Rhaleb NE, Dion S, Barabe J, Roussi N, Jukie D, Drapeau G, Regoli D. Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol. 1989;162:419-427.
27. 2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol. 1992;262:R72-R76.